ADC Therapeutics SA has voluntarily paused enrollment of new patients in the Phase 2 LOTIS-9 trial evaluating Zynlonta and rituximab in patients with untreated diffuse large B-cell lymphoma. This decision comes after a review of data from the 40 patients enrolled in the trial, which indicated potentially excessive respiratory-related events. The company does not expect to report additional data from the trial by the end of the year. ADCT shares are down 15.60% at $2.00 during the premarket session.